A trata sau a nu trata depresia în perioada gravidităţii? O provocare terapeutică

 To treat or not to treat depression during pregnancy? A therapeutic challenge

First published: 18 aprilie 2022

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/Psih.68.1.2022.6306


Depression during pregnancy and in the perinatal period, which newly occurs in women or in those who have already had a history of major depressive episodes, raises several ethical issues when it comes to the management of these cases. In recent years, numerous studies have addressed this issue, and the findings indicate that there is no valid universal protocol and that all factors must be considered to find the best option for both the mother and the fetus. Pregnancy has long been considered a contraindication to antidepressant treatment, thus neglecting the disease itself and the possibility of decompensation of psychoaffective status which is already frequently altered during gestation. Studies have mainly focused on possible malformations related to antidepressants, and have not taken into account that depression itself, untreated, can lead to serious and extremely various maternal or fetal complications. Herein, we want to highlight the accurate evidence regarding effective medical treatments and potential side effects for treating depression in pregnancy and in the postpartum period. The most common question remains: Do we treat depression in pregnancy? Also, it is mandatory for the woman to be involved in making the decision regarding the therapeutic plan after she is explained what the potential possible adverse effects of the drugs are, but also the negative effects of not receiving the treatment.

depression, pregnancy, antidepressant, postpartum


Depresia apărută prima dată în timpul sarcinii şi în perioada perinatală sau depresia din sarcină la femeile care au avut deja antecedente de episoade depresive majore ridică mai multe probleme etice când vine vorba de managementul acestor cazuri. În ultimii ani, numeroase studii au abordat această problemă, iar constatările indică faptul că nu există un protocol universal valabil şi că toţi factorii trebuie luaţi în considerare pentru a găsi cea mai bună opţiune de tratament atât pentru mamă, cât şi pentru făt. Sarcina a fost considerată de multă vreme o contraindicaţie a tratamentului antidepresiv, neglijând astfel boala în sine şi posibilitatea decompensării statutului psihoafectiv, care este de multe ori alterat în timpul gestaţiei. Studiile s-au concentrat în principal pe posibile malformaţii legate de antidepresive şi nu au luat în considerare faptul că depresia în sine, netratată, poate duce la complicaţii grave şi extrem de diverse materne sau fetale. În acest articol dorim să evidenţiem dovezile ştiinţifice privind eficacitatea tratamentelor medicale şi potenţialele efecte secundare pentru tratarea depresiei în sarcină şi în perioada lăuziei. Cea mai frecventă întrebare rămâne: tratăm depresia în sarcină? De asemenea, este obligatoriu ca femeia să se implice în luarea deciziei privind planul terapeutic, după ce i se explică care sunt potenţialele efecte adverse posibile ale medicamentelor, dar şi efectele negative ale neadministrării tratamentului.


Depression is a psychiatric pathology with a prevalence of 10% in the general population(1,2) and over 20% in women(3), with the highest frequency being found in the fertile period(4). Thus, cases of pregnant women with depression become a public health problem and have strong legal and moral implications that should be known in detail by each medical professional in order to be able to inform the pregnant woman of all aspects of the therapeutic management, regardless of the chosen one.

According to the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition), the diagnosis of a major depressive episode is based on five or more symptoms present in a period of at least two weeks(5). More than five of the next symptoms are present almost every day, in a two-week period, as revealed by the patient or related by housemate: low mood, loss of energy, fatigue, feelings of insignificance, or inappropriate culpable, agitation, poor concentration, indecisiveness, suicidal ideation or attempt, anhedonia, change in appetite associated with more than 5% body weight loss in a short period of time.

The more severe the depressive episodes are in the past, the greater the risk of developing another episode in the future. In general, about half of the people who have had a major depressive episode will develop another, while the risk after two episodes increases to 80%(6).

Depression is based on two theories regarding ­etiopathogenesis: dysregulation of the hypothalamic-pituitary-adrenal axis (HPA axis), and monoamine theory.

When it comes to HPA axis theory, it is well known that overactivating stress response systems or activating them for long periods leads to an increased secretion of CRH (corticotropin releasing hormone), ACTH (adrenocorticotropic hormone), and cortisol(7-9). Normally, there is a feedback mechanism that regulates this axis. However, during pregnancy, the placenta independently produces several hormones (CRH, ACTH and cortisol) which alters the physiological systems of self-regulation, by down-regulating the autoreceptors in the hypothalamus and anterior pituitary(10). Physiologically, there is an adaptive status in pregnancy through which cortisol receptors are downregulated to protect the conception product from the potential adverse effects of excessive cortisol(8), but in the cases of maternal depression, these systems are overwhelmed.

Serotonin, norepinephrine and dopamine, monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) are monoamines that ensure the physiological functioning of the nervous system. The fine balance between their concentrations gives rise to the mechanisms of emotion regulation(7). Thus, a disorder at their level leads to various imbalances that are encountered in psychiatric pathology. The activity of the serotonin transporter in the postpartum period is higher in women with depression than in those without depression(11). By using positron emission tomography, studies have shown that early postpartum MAO-A levels correlate with decreased estrogen levels, thus laying the groundwork for postnatal depression(12).

Estrogen and progesterone, through their varying levels in pregnancy versus outside it, can also induce mental imbalances, having a recognized impact on the regulation of neurotransmitters(8). It is generally believed that high levels of sex hormones protect women against depression during pregnancy and that their sudden decrease in postpartum is the trigger for depression(13). To verify this hypothesis, a study was conducted where women were supplemented with estrogen for a period of time after giving birth to achieve a gradual decrease and obtain easily adaptive estrogen levels. The women treated like that no longer showed depressive symptoms and, thus, the relationship between hormonal balance and the mental status was demonstrated once again(14,15).

Another problem is the addressability to the doctor. Only 25.5% of nonpregnant women with a mood disorder received mental services in the prior year, whereas only 14.3% of pregnant women did(16). Due to this, unfortunately, the number of pregnant women with depression that is properly diagnosed is low and, subsequently, the number of the ones who are treated is extremely small. This problem is caused by the fact that there is still stigmatization of people with psychiatric pathologies and the addressability to the doctor is still far below the optimal limit of the entire population. Moreover, when it comes to pregnancy, there are still women who choose not to have any control during pregnancy.

Regarding the timing of depressive episodes, variability is the keyword. There are studies that have shown that this pathology is most frequently diagnosed in the second trimester, followed by the postpartum period. Contrary to old expectations and theories, the prevalence of depression is higher in pregnancy than in the postpartum period in terms of major depressive episodes(17). Major depressive disorders are estimated in 12.7% of cases during pregnancy, with manifestation in the postpartum period in 19.2% of cases.

In the cases of women stopping antidepressants before pregnancy, they have a 68% risk of decompensating the disease, 50% during the first trimester, and 90% in the second trimester(18).

Einarson et al. showed that 70.3% of women who stopped the treatment had side effects like tremors or even suicidal episodes(19). Roca et al. showed that 57% of women who stopped antidepressants were forced to resume the treatment, 48% of them during the first trimester(20).

It has been shown that about half of women with postnatal depression already had depressive episodes during and even before pregnancy(21).

To support the treatment of depression, another study shows that 20% of postpartum deaths are due to suicide, with this being the second leading cause of death in the postpartum period(22).

The effects of depression during pregnancy

Depression during pregnancy has adverse effects on both women and the fetus. Stopping the antidepressant medication leads to the accentuation of the depressive episodes as intensity and to the diminution of the interval between them, with the possible afferent complications. Depression during pregnancy has been shown to be associated with premature birth(23,24), low birth weight(25), fetal growth restriction(26,27) and multiple postnatal complications(8,24,28).

The postnatal complications may include malformations across multiple organ systems, such as eye, ear, respiratory, digestive, skin, musculoskeletal and genitourinary(29). Cases of orofacial defects (cleft palate and lip) and cardiac defects such as tetralogy of Fallot have also been reported in the literature(30).

The concentration of cortisol in girls exposed to maternal depression is higher than normal(31,32). This hormonal change frequently extends, at least during adolescence, thus increasing the risk of developing mental pathologies(33).

In the mild forms, there is a delay in the neuropsychomotor development until the age of 18 months old(34) which can later be outlined by internalizing and externalizing behaviors, fearful temperament and anxiety(35-37). In late childhood and adolescence, children who have been exposed in the intrauterine life to biochemical-humoral disorders caused by maternal depression may develop altered stress response, attention deficit hyperactivity disorder, anxiety and depression(38-40).

Depression and anxiety can activate the glucocorticoid cascade during pregnancy and the inflammatory response, which affects fetal growth and the nervous system development. Thus, changes in brain structures that are important in regulating emotions, such as the fetal amygdala, may also occur(41).

Moreover, it has also been shown that the exposure of conception products to maternal depression during intrauterine life causes epigenetic changes that are detectable at birth (DNA methylation changes) and which persist in the adult brain(42).

From a genetic point of view, an inversely proportional relationship between telomere length and intrauterine stress exposure has been demonstrated(43). This change predisposes to a higher risk of developing various pathologies during life, due to their essential role in chromosomal integrity.

Treatment of depression in pregnancy

There is no general recommendation regarding the treatment of perinatal depression, and an individualized approach for each case is necessary(44,45).

Depending on the severity of the depressive episodes, there are several treatment methods: behavioral treatments, antidepressant medication, alternative somatic treatment, and other forms of treatment such as bright light therapy and exercise.

Behavioral treatments, also named psychosocial and psychological treatments for depression, may be recommended for women with mild or mild-moderate depression. This treatment option can be applied alone or together with drug therapy. These treatment variants consist of: group psychoeducation(46-49), antenatal and/or postnatal classes(50,51), nondirective counseling(52,53), interpersonal psychotherapy(54-58), cognitive behavioral therapy(59-64) and postpartum debriefing before leaving the hospital or clinic(65-67).

Additionally, selective serotonin reuptake inhibitors (SSRI) antidepressants are the most common class of drugs prescribed to pregnant women(68).

The dose of antidepressants should be chosen such as it is the smallest dose to which the patient responds and to which the possible negative effects on pregnancy are minimal. When choosing this dose, it should be taken into account the fact that, during pregnancy, changes in pharmacokinetics such as cytochrome P (CYP) 450 isoenzymes that metabolize SSRIs are altered(69), CYP3A4, CYP2D6, CYP2C9 and CYP2A6 activity is increased, and thus the metabolism of the drug becomes faster. Therefore, in order to achieve optimal plasma concentrations, the dose should be increased. On the other hand, the activity of CYP1A2 and CYP2C19 is low during pregnancy, which leads to a slower metabolism of the active substances predominantly metabolized by these enzymes(70-74).

Alternative somatic treatment options

Electroconvulsive therapy is rarely used to treat major depressive episodes that do not respond to other therapeutic options. It requires general anesthesia which has its own unfavorable effects on the product of conception(75).

Thus, in pregnancy, this method of treatment is rarely used, except for severe cases, with suicidal tendencies, with psychotic manifestations, which primarily endanger the mother’s life.

Other alternative treatments include psychotherapy, exercise(76), massage therapy(77,78) and bright light therapy(79,80). These alternative treatment options can only be applied in cases of mild depression.

Estrogens have also been considered in the postpartum treatment regimen(14,15), but there are insufficient data to prove their benefit in the treatment of depression when considering the numerous thrombotic effects in the immediate postpartum period.

To quantify the effectiveness of any treatment against depression, the severity of symptoms is measured by the 10-item Edinburgh Postnatal Depression Scale for which the recommended cutoff is 15 for MDD Evans 2001. Alternatively, the Edinburgh Postnatal Depression Scale is used to monitor the effectiveness of Spinelli psychotherapy 2003 and Ververs pharmacotherapy 2009.

Adverse effects of antidepressant treatment

Antidepressant use during pregnancy has been associated with various adverse effects on the fetus, including malformations(24), neonatal problems(81) and autism(82). In the studies describing these side effects in intrauterine and neonatal development, it is necessary to distinguish between the side effects of the treatment and the ones caused by the influence of maternal depression on the fetus. This aspect must be considered as much as possible in each research study to be able to draw the appropriate conclusions, as close as possible the statistically important truth(82,83). Neonatal “adaptation” problems, however, seem to be caused by treatment(81). On the other hand, malformations like septal heart defects are still disputed and do not appear to be a cause of the medication itself(24).

A study by Kjaersgaard et al. (2013), on a population of women without a diagnosis of depression, showed that the use of antidepressants during pregnancy was associated with an increased risk of miscarriage. However, compared to cases where women did not take antidepressant treatment, the risk no longer existed, and thus the abortion could no longer be considered an adverse effect of medication(84).

Vasilakis-Scaramozza et al. compared a group of women who had been exposed to tricyclics or selective serotonin reuptake inhibitors (SSRIs) during first-trimester pregnancy with another group of pregnant women with no exposure. The article shows that the risk of developing malformations fetal growth does not increase with tricyclic or SSRI(85). The same conclusion emerges from the meta-analysis performed by Grigoriadis et al.(24)

Numerous studies have shown a link between antidepressant treatment during pregnancy, especially paroxetine, and possible fetal heart defects. In contrast, Einarson et al. argue that precisely this concern associated with the paroxetine treatment would lead to more frequent checkups of newborns from mothers treated with this SSRI than of other newborns. There is no protocol for routine examinations to rule out heart malformations, therefore their frequency in the general population sometimes remains uncertain(86). Cases of neonatal adaptation syndrome have also been described in the literature, and these are defined as a combination of signs and symptoms such as increased muscle tone, tremulousness, feeding and sleep problems, jitteriness and respiratory difficulties. There is a significant similarity between this and the newborn’s withdrawal syndrome, although there are authors who have considered it to be due to drug toxicity. This syndrome was found in pregnant women who received antidepressant medication in the third trimester(87,88). However, it is important to keep in mind that this syndrome is mild, self-limiting and reversible in 3-5 days without remote effects(89). Autism is also a controversial side effect. Rai et al. conducted a study to show that there is a link between antidepressant treatment and an increased incidence of autism without intellectual disability (“high functioning autism” and Asperger’s syndrome)(90). However, in these cases, it is also unclear whether autism had developed due to maternal depression, in which case it was not the drug itself that would have generated the pathology, but its insufficient dose.

Nulman et al. prospectively followed‑up children born to depressed mothers who did not receive treatment and to mothers who received venlafaxine or SSRI. The authors aimed to determine the long-term effects of these treatments. Children in this series were tested at 3 years, 6 years, and at 11 months of mothers with untreated maternal depression. Those whose mothers took SSRIs or venlafaxine had intellectual quotients scores, (IQs) between 105 and 108. The severity of a mother's depression during pregnancy was the greatest predictor of behavioral problems. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcomes. The mother's IQ was the best predictor of the child's IQ(91).


Many of the side effects of antidepressants described so far in the literature are in fact also influenced by the effects of maternal depressive status on the development of the newborn. Thus, it is not advisable to perpetuate the idea that maternal depression should not be treated to avoid the possible adverse effects on the fetus. Moreover, most studies on this topic are retrospective and there is no certainty that pregnant women have actually received the recommended treatment.

Depression is one of the most common pathologies found in the current population, and it is the most common one in women during the fertile period. Thus, women should be encouraged to consult specialists for regular checkups and whenever they consider that an improvement in their mental state can be made. In this case, it is necessary that they are explained in detail each variant of treatment.

It is also the duty of both obstetricians and psychiatrists to know the treatment possibilities and risks of each one to be able to present them to patients and, together with them, to choose the most appropriate scheme for each one of them. It is well known that the patient often chooses the doctor’s recommendation when put in the situation of choosing between several treatment options and, because of this, the physician’s recommendation must be relevant and supported by the latest publications in the literature. 


Disclaimer: The authors declare no conflicts of interest.


  1. Kessing LV. Epidemiology of subtypes of depression. Acta Psychiatr Scand Suppl. 2007;(433):85-9. doi: 10.1111/j.1600-0447.2007.00966.x. 

  2. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119-38. doi: 10.1146/annurev-publhealth-031912-114409. 

  3. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993 Oct-Nov;29(2-3):85-96. doi: 10.1016/0165-0327(93)90026-g. 

  4. Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU. Sex differences in rates of depression: cross-national perspectives. J Affect Disord. 1993 Oct-Nov;29(2-3):77-84. doi: 10.1016/0165-0327(93)90025-f.

  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: 5th Ed. Washington, DC, 2013.  

  6. Rush AJ, Golden WE, Hall GW, Herrera M, Houston A, Kathol RG, et al. Depression in primary care: volume 2. Treatment of major depression. Clinical Practice Guideline Number 5. Rockville (MD): Agency for Health Care Policy and Research; 1993.

  7. Roy A, Campbell MK. A unifying framework for depression: bridging the major biological and psychosocial theories through stress. Clin Invest Med. 2013 Aug 1;36(4):E170-90. doi: 10.25011/cim.v36i4.19951. 

  8. Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol. 2011 Apr;117(4):961-977. doi: 10.1097/AOG.0b013e31821187a7. 

  9. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry. 2015 Feb;20(1):32-47. doi: 10.1038/mp.2014.163. 

  10. Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med. 1998 Aug 1;129(3):229-40. doi: 10.7326/0003-4819-129-3-199808010-00012. 

  11. Doornbos B, Fekkes D, Tanke MA, de Jonge P, Korf J. Sequential serotonin and noradrenalin associated processes involved in postpartum blues. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1320-5. doi: 10.1016/j.pnpbp.2008.04.010. 

  12. Sacher J, Wilson AA, Houle S, Rusjan P, Hassan S, Bloomfield PM, Stewart DE, Meyer JH. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry. 2010 May;67(5):468-74. doi: 10.1001/archgenpsychiatry.2010.32.

  13. Stahl SM. Natural estrogen as an antidepressant for women. J Clin Psychiatry. 2001 Jun;62(6):404-5. doi: 10.4088/jcp.v62n0601. 

  14. Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology (Berl). 1999 Sep 1;146(1):108-10. doi: 10.1007/s002130051095. 

  15. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996 Apr 6;347(9006):930-3. doi: 10.1016/s0140-6736(96)91414-2. PMID: 8598756.

  16. Vesga-López O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008 Jul;65(7):805-15. doi: 10.1001/archpsyc.65.7.805. 

  17. Gaynes BN, Gavin N, Meltzer-Brody S, Lohr KN, Swinson T, Gartlehner G, Brody S, Miller WC. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005 Feb;(119):1-8. doi: 10.1037/e439372005-001. 

  18. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006 Feb 1;295(5):499-507. doi: 10.1001/jama.295.5.499. Erratum in: JAMA. 2006 Jul 12;296(2):170. 

  19. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci. 2001 Jan;26(1):44-8. 

  20. Roca A, Imaz ML, Torres A, Plaza A, Subirà S, Valdés M, Martin-Santos R, Garcia-Esteve L. Unplanned pregnancy and discontinuation of SSRIs in pregnant women with previously treated affective disorder. J Affect Disord. 2013 Sep 25;150(3):807-13. doi: 10.1016/j.jad.2013.02.040. 

  21. Dietz PM, Williams SB, Callaghan WM, Bachman DJ, Whitlock EP, Hornbrook MC. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry. 2007 Oct;164(10):1515-20. doi: 10.1176/appi.ajp.2007.06111893. 

  22. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. 2005 Jun;8(2):77-87. doi: 10.1007/s00737-005-0080-1. 

  23. Szegda K, Markenson G, Bertone-Johnson ER, Chasan-Taber L. Depression during pregnancy: a risk factor for adverse neonatal outcomes? A critical review of the literature. J Matern Fetal Neonatal Med. 2014 Jun;27(9):960-7. doi: 10.3109/14767058.2013.845157. 

  24. Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Radford K, Martinovic J, Ross LE. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013 Apr;74(4):e321-41. doi: 10.4088/JCP.12r07968.

  25. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010 Oct;67(10):1012-24. doi: 10.1001/archgenpsychiatry.2010.111. 

  26. Ciesielski TH, Marsit CJ, Williams SM. Maternal psychiatric disease and epigenetic evidence suggest a common biology for poor fetal growth. BMC Pregnancy Childbirth. 2015 Aug 25;15:192. doi: 10.1186/s12884-015-0627-8. 

  27. Davalos DB, Yadon CA, Tregellas HC. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health. 2012 Feb;15(1):1-14. doi: 10.1007/s00737-011-0251-1. 

  28. ACOG Committee on Practice Bulletins – Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008 Apr;111(4):1001-20. doi: 10.1097/AOG.0b013e31816fd910. 

  29. Tegethoff M, Greene N, Olsen J, Schaffner E, Meinlschmidt G. Stress during pregnancy and offspring pediatric disease: A National Cohort Study. Environ Health Perspect. 2011 Nov;119(11):1647-52. doi: 10.1289/ehp.1003253. 

  30. Carmichael SL, Shaw GM, Yang W, Abrams B, Lammer EJ. Maternal stressful life events and risks of birth defects. Epidemiology. 2007 May;18(3):356-61. doi: 10.1097/01.ede.0000259986.85239.87. 

  31. Ashman SB, Dawson G, Panagiotides H, Yamada E, Wilkinson CW. Stress hormone levels of children of depressed mothers. Dev Psychopathol. 2002 Spring;14(2):333-49. doi: 10.1017/s0954579402002080. 

  32. Essex MJ, Klein MH, Cho E, Kalin NH. Maternal stress beginning in infancy may sensitize children to later stress exposure: effects on cortisol and behavior. Biol Psychiatry. 2002 Oct 15;52(8):776-84. doi: 10.1016/s0006-3223(02)01553-6. 

  33. Halligan SL, Herbert J, Goodyer IM, Murray L. Exposure to postnatal depression predicts elevated cortisol in adolescent offspring. Biol Psychiatry. 2004 Feb 15;55(4):376-81. doi: 10.1016/j.biopsych.2003.09.013. 

  34. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG. 2008 Jul;115(8):1043-51. doi: 10.1111/j.1471-0528.2008.01752.x. 

  35. Graignic-Philippe R, Dayan J, Chokron S, Jacquet AY, Tordjman S. Effects of prenatal stress on fetal and child development: a critical literature review. Neurosci Biobehav Rev. 2014 Jun;43:137-62. doi: 10.1016/j.neubiorev.2014.03.022. 

  36. Glover V. Maternal depression, anxiety and stress during pregnancy and child outcome; what needs to be done. Best Pract Res Clin Obstet Gynaecol. 2014 Jan;28(1):25-35. doi: 10.1016/j.bpobgyn.2013.08.017. 

  37. O’Donnell KJ, Glover V, Barker ED, O’Connor TG. The persisting effect of maternal mood in pregnancy on childhood psychopathology. Dev Psychopathol. 2014 May;26(2):393-403. doi: 10.1017/S0954579414000029. 

  38. Waters CS, Hay DF, Simmonds JR, van Goozen SH. Antenatal depression and children’s developmental outcomes: potential mechanisms and treatment options. Eur Child Adolesc Psychiatry. 2014 Oct;23(10):957-71. doi: 10.1007/s00787-014-0582-3. 

  39. Stein A, Pearson RM, Goodman SH, Rapa E, Rahman A, McCallum M, Howard LM, Pariante CM. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014 Nov 15;384(9956):1800-19. doi: 10.1016/S0140-6736(14)61277-0. 

  40. Pearson RM, Evans J, Kounali D, Lewis G, Heron J, Ramchandani PG, O’Connor TG, Stein A. Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry. 2013 Dec;70(12):1312-9. doi: 10.1001/jamapsychiatry.2013.2163. 

  41. O’Donnell KJ, Meaney MJ. Fetal Origins of Mental Health: The Developmental Origins of Health and Disease Hypothesis. Am J Psychiatry. 2017 Apr 1;174(4):319-328. doi: 10.1176/appi.ajp.2016.16020138. 

  42. Nemoda Z, Massart R, Suderman M, Hallett M, Li T, Coote M, Cody N, Sun ZS, Soares CN, Turecki G, Steiner M, Szyf M. Maternal depression is associated with DNA methylation changes in cord blood T lymphocytes and adult hippocampi. Transl Psychiatry. 2015 Apr 7;5(4):e545. doi: 10.1038/tp.2015.32. 

  43. Send TS, Gilles M, Codd V, Wolf I, Bardtke S, Streit F, Strohmaier J, Frank J, Schendel D, Sütterlin MW, Denniff M, Laucht M, Samani NJ, Deuschle M, Rietschel M, Witt SH. Telomere Length in Newborns is Related to Maternal Stress During Pregnancy. Neuropsychopharmacology. 2017 Nov;42(12):2407-2413. doi: 10.1038/npp.2017.73. 

  44. Weisskopf E, Fischer CJ, Bickle Graz M, Morisod Harari M, Tolsa JF, Claris O, Vial Y, Eap CB, Csajka C, Panchaud A. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opin Drug Saf. 2015 Mar;14(3):413-27. doi: 10.1517/14740338.2015.997708. 

  45. Stohl H, Kohm AD, Dossett E. A rock and a hard place: The selective serotonin reuptake inhibitor dilemmas in addressing perinatal mood and anxiety disorders. J Neonatal Perinatal Med. 2016;9(1):1-5. doi: 10.3233/NPM-16915057. 

  46. Morgan M, Matthey S, Barnett B, Richardson C. A group programme for postnatally distressed women and their partners. J Adv Nurs. 1997 Nov;26(5):913-20. doi: 10.1046/j.1365-2648.1997.00433.x. 

  47. Honey KL, Bennett P, Morgan M. A brief psycho-educational group intervention for postnatal depression. Br J Clin Psychol. 2002 Nov;41(Pt 4):405-9. doi: 10.1348/014466502760387515. 

  48. Misri S, Kostaras X, Fox D, Kostaras D. The impact of partner support in the treatment of postpartum depression. Can J Psychiatry. 2000 Aug;45(6):554-8. doi: 10.1177/070674370004500607. 

  49. Ngai FW, Chan SW, Ip WY. The effects of a childbirth psychoeducation program on learned resourcefulness, maternal role competence and perinatal depression: a quasi-experiment. Int J Nurs Stud. 2009 Oct;46(10):1298-306. doi: 10.1016/j.ijnurstu.2009.03.007. 

  50. Brugha TS, Wheatley S, Taub NA, Culverwell A, Friedman T, Kirwan P, Jones DR, Shapiro DA. Pragmatic randomized trial of antenatal intervention to prevent post-natal depression by reducing psychosocial risk factors. Psychol Med. 2000 Nov;30(6):1273-81. doi: 10.1017/s0033291799002937. 

  51. Reid M, Glazener C, Murray GD, Taylor GS. A two-centred pragmatic randomised controlled trial of two interventions of postnatal support. BJOG. 2002 Oct;109(10):1164-70. doi: 10.1111/j.1471-0528.2002.01306.x. 

  52. Holden JM, Sagovsky R, Cox JL. Counselling in a general practice setting: controlled study of health visitor intervention in treatment of postnatal depression. BMJ. 1989 Jan 28;298(6668):223-6. doi: 10.1136/bmj.298.6668.223. 

  53. Wickberg B, Hwang CP. Counselling of postnatal depression: a controlled study on a population based Swedish sample. J Affect Disord. 1996 Jul 29;39(3):209-16. doi: 10.1016/0165-0327(96)00034-1. 

  54. Stuart S, O’Hara MW. Treatment of postpartum depression with interpersonal psychotherapy. Arch Gen Psychiatry. 1995 Jan;52(1):75-6. doi: 10.1001/archpsyc.1995.03950130075009. 

  55. Spinelli MG. Interpersonal psychotherapy for depressed antepartum women: a pilot study. Am J Psychiatry. 1997 Jul;154(7):1028-30. doi: 10.1176/ajp.154.7.1028. 

  56. Klier CM, Muzik M, Rosenblum KL, Lenz G. Interpersonal psychotherapy adapted for the group setting in the treatment of postpartum depression. J Psychother Pract Res. 2001 Spring;10(2):124-31. 

  57. Zlotnick C, Miller IW, Pearlstein T, Howard M, Sweeney P. A preventive intervention for pregnant women on public assistance at risk for postpartum depression. Am J Psychiatry. 2006 Aug;163(8):1443-5. doi: 10.1176/ajp.2006.163.8.1443

  58. Grote NK, Swartz HA, Geibel SL, Zuckoff A, Houck PR, Frank E. A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. Psychiatr Serv. 2009 Mar;60(3):313-21. doi: 10.1176/ 

  59. Meager I, Milgrom J. Group treatment for postpartum depression: a pilot study. Aust N Z J Psychiatry. 1996 Dec;30(6):852-60. doi: 10.3109/00048679609065055. 

  60. Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ. 1997 Mar 29;314(7085):932-6. doi: 10.1136/bmj.314.7085.932. 

  61. Chabrol H, Teissedre F, Saint-Jean M, Teisseyre N, Rogé B, Mullet E. Prevention and treatment of post-partum depression: a controlled randomized study on women at risk. Psychol Med. 2002 Aug;32(6):1039-47. doi: 10.1017/s0033291702006062. 

  62. Cho HJ, Kwon JH, Lee JJ. Antenatal cognitive-behavioral therapy for prevention of postpartum depression: a pilot study. Yonsei Med J. 2008 Aug 30;49(4):553-62. doi: 10.3349/ymj.2008.49.4.553. 

  63. Cooper PJ, Murray L, Wilson A, Romaniuk H. Controlled trial of the short- and long-term effect of psychological treatment of post-partum depression. I. Impact on maternal mood. Br J Psychiatry. 2003 May;182:412-9. 

  64. Mulcahy R, Reay RE, Wilkinson RB, Owen C. A randomised control trial for the effectiveness of group Interpersonal Psychotherapy for postnatal depression. Arch Womens Ment Health. 2010 Apr;13(2):125-39. doi: 10.1007/s00737-009-0101-6. 

  65. Lavender T, Walkinshaw SA. Can midwives reduce postpartum psychological morbidity? A randomized trial. Birth. 1998 Dec;25(4):215-9. doi: 10.1046/j.1523-536x.1998.00215.x. 

  66. Small R, Lumley J, Donohue L, Potter A, Waldenström U. Randomised controlled trial of midwife led debriefing to reduce maternal depression after operative childbirth. BMJ. 2000 Oct 28;321(7268):1043-7. doi: 10.1136/bmj.321.7268.1043. 

  67. Priest SR, Henderson J, Evans SF, Hagan R. Stress debriefing after childbirth: a randomised controlled trial. Med J Aust. 2003 Jun 2;178(11):542-5. doi: 10.5694/j.1326-5377.2003.tb05355.x. 

  68. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S; National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011 Jul;205(1):51.e1-8. doi: 10.1016/j.ajog.2011.02.029. Epub 2011 Apr 22. 

  69. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999 Oct;24(5):339-46. doi: 10.1046/j.1365-2710.1999.00246.x. 

  70. Stika C, Frederiksen M. 2001. Drug therapy in pregnant and nursing women. In Atkinson AJ Jr, Daniels CE, Dedrick RL, editors. Principles of clinical pharmacology. New York, NY: Academic Press. pp. 277–291

  71. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008 Apr;69(4):652-8. doi: 10.4088/jcp.v69n0419. 

  72. Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry. 2011 Jul;72(7):994-1001. doi: 10.4088/JCP.10m06461. 

  73. Freeman MP, Nolan PE Jr, Davis MF, Anthony M, Fried K, Fankhauser M, Woosley RL, Moreno F. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008 Dec;28(6):646-53. doi: 10.1097/JCP.0b013e31818d2048. 

  74. Avram MJ, Stika CS, Rasmussen-Torvik LJ, Ciolino JD, Pinheiro E, George AL Jr, Wisner KL. Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression. Clin Pharmacol Ther. 2016 Jul;100(1):31-3. doi: 10.1002/cpt.375. 

  75. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006 Aug;63(8):898-906. doi: 10.1001/archpsyc.63.8.898. 

  76. Armstrong K, Edwards H. The effects of exercise and social support on mothers reporting depressive symptoms: a pilot randomized controlled trial. Int J Ment Health Nurs. 2003 Jun;12(2):130-8. doi: 10.1046/j.1440-0979.2003.00229.x. 

  77. Onozawa K, Glover V, Adams D, Modi N, Kumar RC. Infant massage improves mother-infant interaction for mothers with postnatal depression. J Affect Disord. 2001 Mar;63(1-3):201-7. doi: 10.1016/s0165-0327(00)00198-1. 

  78. Field T, Diego MA, Hernandez-Reif M, Schanberg S, Kuhn C. Massage therapy effects on depressed pregnant women. J Psychosom Obstet Gynaecol. 2004 Jun;25(2):115-22. doi: 10.1080/01674820412331282231.

  79. Oren DA, Wisner KL, Spinelli M, Epperson CN, Peindl KS, Terman JS, Terman M. An open trial of morning light therapy for treatment of antepartum depression. Am J Psychiatry. 2002 Apr;159(4):666-9. doi: 10.1176/appi.ajp.159.4.666. 

  80. Epperson CN, Terman M, Terman JS, Hanusa BH, Oren DA, Peindl KS, Wisner KL. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. J Clin Psychiatry. 2004 Mar;65(3):421-5. doi: 10.4088/jcp.v65n0319. 

  81. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K. Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics. 2016 Nov;138(5):e20160181. doi: 10.1542/peds.2016-0181. 

  82. Sørensen MJ, Grønborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, Pedersen LH. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol. 2013 Nov 15;5:449-59. doi: 10.2147/CLEP.S53009. 

  83. Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, Lichtenstein P, Larsson H, D’Onofrio BM. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy with Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA. 2017 Apr 18;317(15):1553-1562. doi: 10.1001/jama.2017.3413. 

  84. Kjaersgaard MI, Parner ET, Vestergaard M, Sørensen MJ, Olsen J, Christensen J, Bech BH, Pedersen LH. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS One. 2013 Aug 28;8(8):e72095. doi: 10.1371/journal.pone.0072095. 

  85. Vasilakis-Scaramozza C, Aschengrau A, Cabral H, Jick SS. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy. 2013 Jul;33(7):693-700. doi: 10.1002/phar.1211. 

  86. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008 Jun;165(6):749-52. doi: 10.1176/appi.ajp.2007.07060879. Epub 2008 Apr 1. Erratum in: Am J Psychiatry. 2008 Jun;165(6):777. Erratum in: Am J Psychiatry. 2008 Sep;165(9):1208. 

  87. Ferreira E, Carceller AM, Agogué C, Martin BZ, St-André M, Francoeur D, Bérard A. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007 Jan;119(1):52-9. doi: 10.1542/peds.2006-2133. 

  88. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005 May 18;293(19):2372-83. doi: 10.1001/jama.293.19.2372. 

  89. Robinson GE. Controversies about the use of antidepressants in pregnancy. 
    J Nerv Ment Dis. 2015 Mar;203(3):159-63. doi: 10.1097/NMD.0000000000000256. 

  90. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013 Apr 19;346:f2059. doi: 10.1136/bmj.f2059. 

  91. Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012 Nov;169(11):1165-74. doi: 10.1176/appi.ajp.2012.11111721.

Articole din ediţiile anterioare

DIAGNOSTIC MODERN | Ediţia 3 / 2016

Un diagnostic funcţional al tulburărilor depresive

Dragoș Cîrneci, Stanca Pleș, Gabriela Cătău

Pe măsură ce neuroștiinţele află tot mai multe despre creier, se apropie momentul în care diagnosticul se va baza mai degrabă pe scanarea creierulu...

19 aprilie 2017
CLINIC | Ediţia 4 51 / 2017

Depresia la vârsta a treia – aspecte clinice

Delia Marina Podea

Depresia la vârsta a treia, una dintre cele mai frecvente entități nosologice, este deseori subdiagnosticată și subtratată. Diagnosticul precoce și...

08 ianuarie 2018
REVIEW | Ediţia 2 69 / 2022

Analiza transnosografică a disfuncţiei executive – dimensiuni clinice, psihometrice şi terapeutice

Octavian Vasiliu

Analiza disfuncţiei executive la pacienţii cu tulburări psihice prezintă interes din punct de vedere clinic şi terapeutic, având în vedere cercetăr...

30 iunie 2022

Despre rost și depresie.

Dan Pereţianu, Aurelian Nebel, Sorin Şuba, Denis Păduraru

Scurte consideraţii lingvistico-medicale

02 februarie 2017